Cornea · 2011
Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chu Hsiao-Sang, Hu Fung-Rong, Yang Chung-May, Yeh Po-Ting, Chen Yan-Ming, Hou Yu-Chih, Chen Wei-Li
Аннотация
PURPOSE: To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy.
METHODS: A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests.
RESULTS: After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects.
CONCLUSIONS: The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.
METHODS: A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests.
RESULTS: After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects.
CONCLUSIONS: The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabChildConjunctivaCorneal NeovascularizationFemaleHumansInjectionsLipid MetabolismLipid Metabolism DisordersMaleMiddle AgedVascular Endothelial Growth Factor AVisual AcuityYoung Adult